Modulators of pnpla3 expression
AssigneeIonis Pharmaceuticals, Inc.
InventorsSusan M. FREIER, Huynh-Hoa BUI
Life of this patent
Estimating the term…
Abstract
The present embodiments provide methods, compounds, and compositions useful for inhibiting PNPLA3 expression, which may be useful for treating, preventing, or ameliorating a disease associated with PNPLA3.
Claims12
1-41. (canceled)
A method of treating, preventing, or ameliorating a disease associated with PNPLA3 in an individual comprising administering to the individual a compound, wherein the anionic form of the compound has the following formula (SEQ ID NO:
- 1089):
- or a pharmaceutically acceptable salt thereof, thereby treating, preventing, or ameliorating the disease.
(canceled)
(canceled)
A method of inhibiting expression of PNPLA3 in a cell comprising contacting the cell with a compound, wherein the anionic form of the compound has the following formula (SEQ ID NO:
- 1089):
- or a pharmaceutically acceptable salt thereof, thereby inhibiting expression of PNPLA3 in the cell.
A method of reducing or inhibiting liver damage, steatosis, liver fibrosis, liver inflammation, liver scarring or cirrhosis, liver failure, liver enlargement, elevated transaminases, or hepatic fat accumulation in an individual, comprising administering a compound, wherein the anionic form of the compound has the following formula (SEQ ID NO:
- 1089):
- or a pharmaceutically acceptable salt thereof, to the individual, thereby reducing or inhibiting liver damage, steatosis, liver fibrosis, liver inflammation, liver scarring or cirrhosis, liver failure, liver enlargement, elevated transaminases, or hepatic fat accumulation in the individual.
52-62. (canceled)
Dependencies are inferred from the claim text.